Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients

Transplant Infectious Disease

Volumn 16, Issue 5, 2014, Pages 744-750

  Huang, A M ^a   Marini, B L ^a   Frame, D ^a   Aronoff, D M ^b   Nagel, J L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Recurrence; Recurrent Clostridium difficile; Stem cell transplant

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CYCLOSPORIN; ENEMA; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS; VANCOMYCIN;

ADULT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; ADVERSE EFFECTS; AGED; CASE CONTROL STUDY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; TIME; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84907955350     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12267     Document Type: Article

References (16)

1. Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012; 18: 1295-1301.
2. Leung S, Metzger BS, Currie BP. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol 2010; 31: 313-315.
3. Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2013; 19 (3): 405-409. Epub 2012 Dec 4.
4. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54 (8): 1053-1063.
5. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 (S2): S77-S787.
6. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-145.
7. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
8. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse-mortality. Bone Marrow Transplant 2000; 26 (8): 871-876.
9. Dubberke ER, Reske KA, Srivastava A, et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010; 24: 192-198.
10. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-193.
11. Leung DY, Kelly CP, Boguniewics M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 18: 633-637.
12. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384-389.
13. Bacon AE 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis 1994; 18: 205-209.
14. Stringer AM, Gibson RJ, Bowen JM, Keefe DMK. Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009; 10 (1): 79-83.
15. Bodet CA 3rd, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother 1985; 28 (3): 437-439.
16. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Soneshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55 (S2): S162-S169.